CARLOS A. DE JONGH, M.D.; STEPHEN C. SCHIMPFF, M.D.; PETER H. WIERNIK, M.D.
To the editor: The recent article by Dekker and colleagues (1) addresses an issue of concern, especially to those treating patients with acute leukemia receiving oral antibiotic prophylaxis: namely, is there a risk of infection with resistant microorganisms?
Since van de Waaij and colleagues (2) advanced the concept of colonization resistance in 1972, selective microbial suppression of the alimentary canal has been explored as an approach to substitute for the use of oral nonabsorbable antibiotics (3, 4) which, although effective in reducing serious infections, also have significant disadvantages (5). Several studies of trimethoprim-sulfamethoxazole or nalidixic acid have been reported or
DE JONGH CA, SCHIMPFF SC, WIERNIK PH. Antibiotic Prophlaxis in Acute Leukemia. Ann Intern Med. ;95:783–784. doi: 10.7326/0003-4819-95-6-783_3
Download citation file:
Published: Ann Intern Med. 1981;95(6):783-784.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use